🏛️ Verified NIH Record • Updated 2026-08-27

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (NCT05421663)

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Janssen Research & Development, LLC

🩺 Plain-English Summary (8th-Grade Level)

This is a Phase 1b/2, multicenter, open-label, study of JNJ-90014496, an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (10 items).

Location: City of Hope — Duarte, California

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • History of symptomatic deep vein thrombosis or pulmonary embolism within six months of apheresis (line associated deep vein thrombosis is allowed)
  • History of stroke, unstable angina, myocardial infarction, congestive heart failure New York Heart Association (NYHA) Class III or IV, severe cardiomyopathy or ventricular arrhythmia requiring medication or mechanical control within 6 months of apheresis
  • History of a seizure disorder, dementia, cerebellar disease or neurodegenerative disorder
  • Known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system
  • Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones)
  • Evidence of active viral or bacterial infection requiring systemic antimicrobial therapy, or uncontrolled systemic fungal infection
  • Diagnosis of Human herpes virus (HHV) 8-positive DLBCL or T cell/histiocyte-rich large B-cell lymphoma or Burkitt and high-grade B-cell lymphoma with 11q aberrations (previously Burkitt-like lymphoma) or Richter's transformation or Lymphomatoid granulomatosis or Plasmablastic lymphoma or Waldenstrom's Macroglobulinemia
  • Any prior solid organ or allogeneic stem cell transplantation
  • Autologous stem cell transplant within 12 weeks of apheresis; Prior CAR-T cell therapy within 12 weeks of apheresis

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (32 Sites)

  • City of Hope — Duarte, California
  • Colorado Blood Cancer Institute — Denver, Colorado
  • University of Iowa Hospital and Clinics — Iowa City, Iowa
  • University of Kentucky Medical Center — Lexington, Kentucky
  • Rutgers Cancer Institute of New Jersey — Piscataway, New Jersey
  • Levine Cancer Institute — Charlotte, North Carolina
  • University Hospitals Cleveland Medical Center — Cleveland, Ohio
  • University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
  • Greco Hainesworth Tennessee Oncology Centers for Research — Nashville, Tennessee
  • Sarah Cannon Research Institute — Nashville, Tennessee
  • St. David's South Austin Medical Center — Austin, Texas
  • MD Anderson Cancer Center — Houston, Texas
  • Texas Transplant Institute — San Antonio, Texas
  • Swedish Cancer Institute — Seattle, Washington
  • St Vincents Hospital Melbourne — Fitzroy,
  • The Alfred Hospital — Melbourne,
  • Fiona Stanley Hospital — Murdoch,
  • Calvary Mater Newcastle Hospital — Waratah,
  • Princess Margaret Cancer Centre University Health Network — Toronto, Ontario
  • Rigshospitalet — Copenhagen,
  • Odense University Hospital — Odense,
  • Erasmus MC — Rotterdam,
  • UMC Utrecht — Utrecht,
  • Seoul National University Hospital — Seoul,
  • Asan Medical Center — Seoul,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗